Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Status:
Not yet recruiting
Trial end date:
2027-01-31
Target enrollment:
Participant gender:
Summary
This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a
CAR-T therapy) and find out what effect, if any, it has on treating patients with
HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not
responded to treatment (refractory). T cells are infection fighting blood cells that can kill
tumor cells. Axicabtagene ciloleucel consists of genetically modified T cells, modified to
recognize CD-19, a protein on the surface of cancer cells. These CD-19-specific T cells may
help the body's immune system identify and kill CD-19-positive B-cell non-Hodgkin lymphoma
cells.